John Mancuso, PhD

John Mancuso is Director of Chemsitry and Head of the Peptide Synthesis Platform at Sygnature Discovery North America. He brings more than 20 years of experience in the pharmaceutical and biopharmaceutical industries, with expertise spanning medicinal chemistry, peptide science, and drug discovery across a range of therapeutic areas. Prior to joining Sygnature, John held scientific positions at MethylGene, Tranzyme Pharma, Université de Sherbrooke, McGill University, and the University of Pittsburgh, where his research focused on epigenetics, metabolic disease, macrocyclic peptides, and small molecule drug discovery.

Drawing on extensive experience in peptide and small molecule therapeutic development, John specializes in supporting clients through complex drug discovery challenges, from early-stage hit identification through lead optimization. His expertise encompasses peptide synthesis, medicinal chemistry strategy, and cross-functional project leadership, helping multidisciplinary teams advance innovative therapeutics efficiently and effectively. His scientific and collaborative approach enables the successful delivery of discovery programs across diverse targets and modalities.